Results 121 to 130 of about 1,738 (143)

Lenalidomide/rituximab/agammaglobulinaemia-tyrosine-kinase-inhibitors

Reactions Weekly, 2023
openaire   +1 more source

Agammaglobulinaemia-tyrosine-kinase-inhibitors/cyclophosphamide/fludarabine

Reactions Weekly, 2023
openaire   +1 more source

X-linked agammaglobulinaemia: A novel single amino acid deletion in the PH region of Bruton's tyrosine kinase (Btk)

Immunology Letters, 1997
S. Pienaar, D.W. Beatty, B. Eley, H. Henderson   +3 more
openaire   +2 more sources

Mutation analysis in Bruton's tyrosine kinase, the X-linked agammaglobulinaemia gene, including identification of an insertional hotspot

Human Molecular Genetics, 1995
H B, Gaspar, L A, Bradley, F, Katz, R C, Lovering, C M, Roifman, G, Morgan, R J, Levinsky, C, Kinnon   +7 more
openaire   +2 more sources

Orphan designation: Agammaglobulinaemia tyrosine kinase, Treatment of pemphigus

Case Medical Research, 2019
openaire   +2 more sources

Improved oligonucleotide primer set for molecular diagnosis of X-linked agammaglobulinaemia: predominance of amino acid substitutions in the catalytic domain of Bruton's tyrosine kinase

Human Molecular Genetics, 1995
I, Vorechovský, L, Luo, G, de Saint Basile, L, Hammarström, A D, Webster, C I, Smith   +5 more
openaire   +2 more sources

Pillars Article: The Gene Involved in X-linked Agammaglobulinaemia Is a Member of the Src Family of Protein-Tyrosine Kinases. Nature. 1993. 361: 226–233

The Journal of Immunology, 2012
David Vetrie, Igor Vořechovský, Paschalis Sideras, Jill Holland, Angela Davies, Frances Flinter, Lennart Hammarström, Christine Kinnon, Roland Levinsky, Martin Bobrow, C I Edvard Smith, David R Bentley   +11 more
openaire   +1 more source

Expression of Bruton's tyrosine kinase in B lymphoblastoid cell lines from X-linked agammaglobulinaemia patients

Clinical and Experimental Immunology, 2003
Robbert J Rottier
exaly  

Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer, 2014
Rudi W Hendriks, Saravanan Y Pillai
exaly  

Targeting non-malignant disorders with tyrosine kinase inhibitors

Nature Reviews Drug Discovery, 2010
Friedrich Grimminger, Ralph T Schermuly
exaly